target is 24c, page-3

I've been targeting 20c in the runup to the ACV1 announcement and 30c post announcement on good news.

I have revised my opinion and now see 23-25c pre announcement and 50c minimum in the immediate aftermath of the announcement, possibly reaching 75c or higher. An announcement of a partnering deal with big pharma for AVC1 would drive the price out of the "penny stock" category.

I base this on what I see as the highly likely possibility of not just good news - but EXCELLENT news - from the sciatica trial, with clear evidence of effectiveness in a trial that was not powered to show this.

Also, ACV1 is likely to attract a much more interest by big pharma than did AOD9604, especially if the company can announce the start of active preclinical work on oral ACV1 in the 3rd quarter. No big pharma company can afford to ignore the prospects opened up by the introduction of the first oral pain medication not an opiate, anti-inflammatory or nsaid.